<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735449</url>
  </required_header>
  <id_info>
    <org_study_id>GMA-COM-07-XTC</org_study_id>
    <nct_id>NCT00735449</nct_id>
  </id_info>
  <brief_title>Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects</brief_title>
  <official_title>Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <brief_summary>
    <textblock>
      Efficacy and safety evaluation of Combigan with timolol when each is used as adjunctive
      therapy to Xalatan in subjects with glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Intraocular Pressure (IOP) at 10 AM at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Mean IOP at 10 AM at week 12. IOP is a measurement of the fluid pressure in the eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Intraocular Pressure (IOP) at 10 AM at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Mean IOP at 10 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Intraocular Pressure (IOP) at 8 AM at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Mean IOP at 8 AM at week 12. IOP is a measurement of the fluid pressure inside the eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Intraocular Pressure (IOP) at 8 AM at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>Mean IOP at 8 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events</measure>
    <time_frame>Week 12</time_frame>
    <description>Number of subjects with adverse events, defined as any untoward medical occurrence in a subject, during the study (reported through the week 12 visit).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Combigan ®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%) adjunctive to Xalatan® (latanoprost 0.005%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol Maleate 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%</intervention_name>
    <description>1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.</description>
    <arm_group_label>Combigan ®</arm_group_label>
    <other_name>Combigan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>timolol maleate 0.5%</intervention_name>
    <description>1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.</description>
    <arm_group_label>Timolol Maleate 0.5%</arm_group_label>
    <other_name>Timpoptic®</other_name>
    <other_name>Timoptol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>latanoprost 0.005%</intervention_name>
    <description>1 drop of latanoprost 0.005% once nightly.</description>
    <arm_group_label>Combigan ®</arm_group_label>
    <arm_group_label>Timolol Maleate 0.5%</arm_group_label>
    <other_name>Xalatan®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age

          -  Give written informed consent

          -  Be in good general health as determined by your doctor

          -  Have a diagnosis of unilateral or bilateral glaucoma or ocular hypertension

          -  If you are a female of child bearing potential, you must be willing to practice
             effective contraception for the duration of the study (i.e., abstinence, spermicide,
             condoms, or birth control pills)

          -  Understand the study instructions, and be able to follow the study instructions; and

          -  Be likely to complete the entire study period (12 weeks), including all regularly
             scheduled study visits

        Exclusion Criteria:

          -  Have any active ocular disease other than glaucoma or ocular hypertension that would
             interfere with study interpretation

          -  History of severe renal or hepatic impairment

          -  Subjects with severe cardiovascular disease should not be enrolled unless their
             disease is controlled and clearance has been obtained from the subject's primary care
             physician and/or cardiologist

          -  Contraindications to beta-adrenoceptor antagonist therapy such as chronic obstructive
             pulmonary disease, bronchial asthma, sinus bradycardia, second and third degree
             atrioventricular block, overt cardiac failure and cardiogenic shock or uncontrolled
             congestive heart failure

          -  Any systemic disease or clinical evidence of any condition which would make the
             subject, in the opinion of the investigator, unsuitable for the study or could
             potentially confound the study results; and

          -  Concurrent participation or prior participation in any investigational drug or device
             study within the last 30 days prior to the screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2008</study_first_posted>
  <results_first_submitted>October 17, 2011</results_first_submitted>
  <results_first_submitted_qc>October 17, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 24, 2011</results_first_posted>
  <last_update_submitted>November 13, 2012</last_update_submitted>
  <last_update_submitted_qc>November 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Brimonidine Tartrate, Timolol Maleate Drug Combination</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combigan®</title>
          <description>Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%)adjunctive to Xalatan® (latanoprost 0.005%)</description>
        </group>
        <group group_id="P2">
          <title>Timolol Maleate 0.5%</title>
          <description>Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combigan®</title>
          <description>Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%)adjunctive to Xalatan® (latanoprost 0.005%)</description>
        </group>
        <group group_id="B2">
          <title>Timolol Maleate 0.5%</title>
          <description>Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="204"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.5" lower_limit="30.1" upper_limit="87.0"/>
                    <measurement group_id="B2" value="65.9" lower_limit="29.8" upper_limit="88.9"/>
                    <measurement group_id="B3" value="65.4" lower_limit="29.8" upper_limit="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Mean Intraocular Pressure (IOP) at 10 AM at Week 6</title>
        <description>Mean IOP at 10 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.</description>
        <time_frame>Week 6</time_frame>
        <population>Per-protocol, which included all patients who started the study (randomized) and had at least one follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Combigan®</title>
            <description>Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%)adjunctive to Xalatan® (latanoprost 0.005%)</description>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
            <description>Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Intraocular Pressure (IOP) at 10 AM at Week 6</title>
          <description>Mean IOP at 10 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.</description>
          <population>Per-protocol, which included all patients who started the study (randomized) and had at least one follow-up visit.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="3.10"/>
                    <measurement group_id="O2" value="16.7" spread="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Intraocular Pressure (IOP) at 10 AM at Week 12</title>
        <description>Mean IOP at 10 AM at week 12. IOP is a measurement of the fluid pressure in the eye.</description>
        <time_frame>Week 12</time_frame>
        <population>Per-protocol, which included all patients who started the study (randomized) and had at least one follow-up visit and who were assessed for this outcome measure at the Week 12 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Combigan®</title>
            <description>Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%)adjunctive to Xalatan® (latanoprost 0.005%)</description>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
            <description>Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Intraocular Pressure (IOP) at 10 AM at Week 12</title>
          <description>Mean IOP at 10 AM at week 12. IOP is a measurement of the fluid pressure in the eye.</description>
          <population>Per-protocol, which included all patients who started the study (randomized) and had at least one follow-up visit and who were assessed for this outcome measure at the Week 12 visit.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="2.59"/>
                    <measurement group_id="O2" value="16.9" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Intraocular Pressure (IOP) at 8 AM at Week 12</title>
        <description>Mean IOP at 8 AM at week 12. IOP is a measurement of the fluid pressure inside the eye.</description>
        <time_frame>Week 12</time_frame>
        <population>Per-protocol, which included all patients who started the study (randomized) and had at least one follow-up visit and who were assessed for this outcome measure at the Week 12 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Combigan®</title>
            <description>Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%)adjunctive to Xalatan® (latanoprost 0.005%)</description>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
            <description>Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Intraocular Pressure (IOP) at 8 AM at Week 12</title>
          <description>Mean IOP at 8 AM at week 12. IOP is a measurement of the fluid pressure inside the eye.</description>
          <population>Per-protocol, which included all patients who started the study (randomized) and had at least one follow-up visit and who were assessed for this outcome measure at the Week 12 visit.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="2.55"/>
                    <measurement group_id="O2" value="17.7" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Intraocular Pressure (IOP) at 8 AM at Week 6</title>
        <description>Mean IOP at 8 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.</description>
        <time_frame>Week 6</time_frame>
        <population>Per-protocol, which included all patients who started the study (randomized) and had at least one follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Combigan®</title>
            <description>Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%)adjunctive to Xalatan® (latanoprost 0.005%)</description>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
            <description>Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Intraocular Pressure (IOP) at 8 AM at Week 6</title>
          <description>Mean IOP at 8 AM at week 6. IOP is a measurement of the fluid pressure inside the eye.</description>
          <population>Per-protocol, which included all patients who started the study (randomized) and had at least one follow-up visit.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="2.87"/>
                    <measurement group_id="O2" value="17.8" spread="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events</title>
        <description>Number of subjects with adverse events, defined as any untoward medical occurrence in a subject, during the study (reported through the week 12 visit).</description>
        <time_frame>Week 12</time_frame>
        <population>Safety population, which included all patients who started the study (randomized) and were treated.</population>
        <group_list>
          <group group_id="O1">
            <title>Combigan®</title>
            <description>Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%)adjunctive to Xalatan® (latanoprost 0.005%)</description>
          </group>
          <group group_id="O2">
            <title>Timolol Maleate 0.5%</title>
            <description>Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events</title>
          <description>Number of subjects with adverse events, defined as any untoward medical occurrence in a subject, during the study (reported through the week 12 visit).</description>
          <population>Safety population, which included all patients who started the study (randomized) and were treated.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Combigan®</title>
          <description>Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%)adjunctive to Xalatan® (latanoprost 0.005%)</description>
        </group>
        <group group_id="E2">
          <title>Timolol Maleate 0.5%</title>
          <description>Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute exacerbation of COPD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President Medical Affairs</name_or_title>
      <organization>Allergan, Inc.</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

